Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category ...

Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...

OXB honoured at 2025 CDMO Leadership Awards Europe in 'Cell & Gene Therapy' category Oxford, UK - 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today ...

Less than two months after OXB revealed an equity raise of 60 million pounds sterling ($81 million) as part a plan to expand its operations in the U.S., the U.K.-based cell and gene therapy ...

Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a ...

OXB has signed and closed an asset purchase transaction to acquire a custom-built cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating. The acquisition ...

OXB, an Oxford-based cell and gene therapy CDMO (contract development and manufacturing organisation), has reported strong half-year results. The firm posted revenues of £73.2m for the six months ...